RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

John T. O’Brien*, Leonidas Chouliaras, Janet Sultana, John-Paul Taylor, Clive Ballard, on behalf of the RENEWAL Study Group

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
7 Downloads (Pure)

Abstract

Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.

Original languageEnglish
Article number169
Pages (from-to)1-17
Number of pages17
JournalAlzheimer's Research and Therapy
Volume14
Issue number1
DOIs
Publication statusPublished - 11 Nov 2022
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint

Dive into the research topics of 'RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus'. Together they form a unique fingerprint.

Cite this